Agency IQ

AUGUST 16, 2024

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. Read AgencyIQ analysis here for a detailed discussion of these issues. ].

FDA 40

FDA Trials Regulations Therapies 40

Drug Discovery World

JULY 1, 2024

million from the Foundation, which had committed itself for a five-year period (2021-2026), with the possibility of extending its support of the centre. billion DKK ($11.97 When this was launched in September 2021, it was supported by a grant of up to $47.5

Disease 162

Disease International Research Science 162

The Pharma Data

NOVEMBER 11, 2020

and EU5 by 2026. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com. The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.

Therapies 40

Therapies Marketing Disease Clinical Research 40

The Pharma Data

DECEMBER 16, 2020

and EU5 by 2026. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com. The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.

Therapies 40

Therapies Marketing Disease Clinical Research 40

The Pharma Data

OCTOBER 14, 2020

Pre-clinical and clinical proof-of-concept data from a first-in-human single dose DSR study demonstrated that single dose DSR therapy was safe and well-tolerated and the positive results were published in the high impact peer-reviewed cardiovascular journal, Circulation. and EU5 by 2026.

Clinical Trials 40

Clinical Trials Clinical Research Therapies Marketing 40

Drug Discovery World

FEBRUARY 22, 2024

There is now hope that new treatments will arise to overcome the limitations of existing therapies and relieve the millions of patients suffering worldwide 4 ”. The report also highlights that the global neuroscience market (GNM) “was worth $612 billion in 2022 and could grow to $721 billion by 2026.

Drugs 147

Drugs Clinical Trials Disease Therapies 147